10th APAC Draft Program

Tuesday, April 13, 2021

@Keidanren-kaikan+WEB

Overcoming COVID-19 and taking on new innovative challenges for the next decade in Asia.

Clock Time JST		Time Required	Session Title	Chair/Speaker/Panelist	
10:30 ▶	10:40	10	Curtain-raiser (video)		
10:40 ▶	10:45	5	Opening Remarks	George Nakayama	JPMA
10:45 ▶	10:55	10	Congratulatory Speech	Thomas Cueni	IFPMA
10:55 ▶	11:25	30	Keynote Lecture	Yasuhiro Fujiwara	PMDA
11:25 ▶	11:35	10	< Break 1 >		
			Regulations and Approvals (RA) Session		
11:35 ▶	12:35	60	"Regulatory agility during/after COVID-19"		
		(20)	Keynote speech	John CW Lim	Duke-NUS
			Panel Discussion Facilitators: Facilitators:	Shinji Hatakeyama Vicky Han	JPMA SAPI
		(40)	Panelists:	Jo-Feng Chi	Taiwan FDA
		(10)	Panelists:	Rosilawati Ahmad	NPRA
			Panelists: Panelists:	Daisuke Koga Sara Wang	PMDA RDPAC
12:35 ▶	13:15	40	< Break 2 (Lunch) >		
13.15	Access To Innovative Medicines (ATIM) Session 1 (e-labeling)				
15.15	"Raise an awareness for benefits of e-labeling in Asia"				
			Co-chairperson	Junko Sato	PMDA
		(5)	Opening Co-chairperson	Rie Matsui	JPMA
		(10) (10)	Current and planned e-labeling initiatives in Japan Current and planned e-labeling initiatives in Taiwan	Sayaka Kurihara Po-Wen Yang	PMDA Taiwan FDA
		(10)	Current and planned e-labeling initiatives in Singapore	Mark Wong	HSA
		(20)	Panel Discussion	All speakers + Nguyen Thanh Lam, [DAV
		(5)	Conclusion	Junko Sato	PMDA
14:15 ▶	14:20	5	< Break 3 >		
14:20 ▶	15:30	70	ATIM Session 2 (Post Approval Change, BCS-ba		
		(1E)	"Promote BE biowaiver based on BCS of ICH M! Position paper/BE biowaiver introduction	9" Tomonori Nakagawa	JPMA
		(15) (15)	Revisions of Japanese BE Guidelines	Ryosuke Kuribayashi	PMDA
		(15)	Explanation of BE study from panelists	Lusia Rizka Andalucia	BPOM
		, ,	Explanation of BE study from panelists	Chien-Liang Lin	Taiwan FDA
		(20)	Panel Discussion Facilitator:	Ryosuke Kuribayashi	PMDA
			Panel Discussion Panelists:	Lusia Rizka Andalucia	BPOM
		(5)	Panel Discussion Panelists: Conclusion	Chien-Liang Lin Ryosuke Kuribayashi	Taiwan FDA PMDA
15:30 ▶	15:35	5	< Break 4 >	Try obtaine Training querin	THIDA
15:35 ▶	16:35	60	Drug Discovery Alliances (DA) Session		
15.55	10.33	00	"Promote cross-border open innovation in Asia to deliver	innovative drugs to people in Asia"	
		(4)	Opening	Atsushi Hasuoka	JPMA
		(20)	Progress update on DSANA	Toru Yoshikawa	JPMA
			(<u>D</u> rug <u>S</u> eeds <u>A</u> lliance <u>N</u> etwork <u>A</u> sia)	Wei-Kuang Chi Jun Terauchi	DCB JPMA
		(32)	Progress update on ANPDC	Sirasak Teparkum	TCELS
			(APAC Natural Product Drug discovery Consortium)	Suparerk Borwornpinyo	ECDD
				Somponnat Sampattavanich Lily Eurwilaichitr	Siriraj HP Biotec
		(4)	Closing	Wei-Kuang Chi	DCB
16:35 ▶	16:40	5	< Break 5 >	<u> </u>	
16:40 ▶	18:10	90	Value-based Healthcare(VBH) Session "Reconsider Value-based Healthcare amid the Covid-19 p	pandemic"	
		(2)	Opening	Tomoyuki Otsuka	JPMA
		(15)	The digital acceleration of healthcare in Asia	Kapur Vikram	Bain & Co.
		(15)	VBH: Recent development and initiatives in Thailand		ngkorn Univ.
		(15)	Value-based Financing towards Universal Health Coverage in Asia	Eduardo Banzon	ADB
		(20)	Data-Driven Health Care System Revisited in the Pandemic Stricken World	Yasuhiro Suzuki	MHLW
		(20)	Panel Discussion Facilitator:	Toshihiko Takeda All speakers+Yasushi Okada	Boston C.
		(3)	Closing	Yasushi Okada	JPMA
18:10 ▶	18:20	10	Closing Remarks	Kenji Yasukawa	JPMA

^{*}Please note the starting time is set JST 10:30 (=UTC + 9 hrs.), which is equivalent to 07:00 at Mumbai, New Delhi; 08:30 at Bangkok, Hanoi, Jakarta; 09:30 at KL, Singapore, Manila, Taipei, Beijing and HK.

^{*} No reception at this time.